Mersana raises $35m, names former Millennium president CEO
This article was originally published in Scrip
Executive Summary
Seventeen-year Millennium Pharmaceuticals veteran Anna Protopapas began her first day as president and CEO of Mersana Therapeutics on 2 March with an announcement that the antibody-drug conjugate (ADC) specialist closed a $35m Series B venture capital round.